摘要
目的:探讨利培酮联合益生菌对酒精所致精神病性障碍患者的治疗效果。方法:选取2020年8月~2023年8月收治的100例酒精所致精神障碍患者,按照计算机生成的序列被随机分配为对照组(基础治疗 利培酮,50例)与观察组(基础治疗 利培酮 益生菌,50例)。比较两组治疗前及治疗8周后临床疗效、阳性与阴性症状量表(PANSS)评分、认知功能、酒精控制情况相关评分及不良反应有无差异。结果:治疗前两组PANSS量表、洛文斯顿作业疗法认知评定量表(LOTCA量表)均无统计学差异;治疗后观察组临床总有效率、LOTCA量表评分显著高于治疗前及对照组(P P P > 0.05)。结论:利培酮联合益生菌治疗酒精所致精神病性障碍总疗效好,可有效改善患者认知功能,且不会增加明显副作用,安全性良好。
Objective: To explore the therapeutic effect of risperidone combined with probiotics on patients with alcohol-induced psychiatric disorders. Methods: 100 patients with alcohol-induced mental disorders admitted to Rongjun Hospital in Linyi City from August 2022 to August 2023 were randomly assigned to a control group (basic treatment risperidone, 50 cases) and an observation group (basic treatment risperidone probiotics, 50 cases) according to a computer-generated sequence. Compare the clinical efficacy, Positive and Negative Syndrome Scores (PANSS), cognitive function, patient alcohol control scores, and adverse reactions between the two groups before and after 8 weeks of treatment. Results: There was no statistically significant difference in PANSS and Loewensteinscores (LOTCA scores) between the two groups before treatment. After treatment, the total clinical effectiveness rate and LOTCA scores of the observation group were significantly higher than those of the pre-treatment and control groups (P P P > 0.05). Conclusion: The combination of risperidone and probiotics has a good overall efficacy in the treatment of alcohol-induced psychiatric disorders, which can effectively improve patients’ cognitive function without significant side effects and has good safety.
出处
《临床医学进展》
2024年第5期654-660,共7页
Advances in Clinical Medicine
